Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FK-PC101 Vaccine in High-Risk Prostate Cancer
NCT06636682Phase 2Recruiting
- Sponsor
- CellVax Therapeutics
- Start
- Oct 2024
- Primary completion
- Feb 2027
- Modality
- Prophylactic Vaccines, Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing FK-PC101 with Standard of Care (2 arms). Primary endpoint: Disease-Free Survival at 22 months. Started Oct 2024; status: recruiting.
02
Drugs
FK-PC101
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06636682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636682.